Edwards Lifesciences Corporation (NYSE:EW) Receives $91.39 Consensus Target Price from Brokerages

Edwards Lifesciences Corporation (NYSE:EW) has been given an average recommendation of “Moderate Buy” by the twenty-eight brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $91.3913.

A number of research firms have commented on EW. Barclays reaffirmed an “overweight” rating and set a $99.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Stifel Nicolaus upped their price target on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Robert W. Baird set a $83.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 31st. Truist Financial boosted their target price on shares of Edwards Lifesciences from $87.00 to $90.00 and gave the company a “hold” rating in a research note on Monday, November 3rd. Finally, JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a report on Friday, October 31st.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.29% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in EW. Parkside Financial Bank & Trust boosted its stake in shares of Edwards Lifesciences by 9.8% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock valued at $114,000 after buying an additional 130 shares during the period. Prosperity Consulting Group LLC raised its holdings in shares of Edwards Lifesciences by 3.2% during the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after acquiring an additional 132 shares in the last quarter. Howard Capital Management Inc. boosted its position in Edwards Lifesciences by 3.3% during the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after purchasing an additional 132 shares during the last quarter. NewSquare Capital LLC grew its stake in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares in the last quarter. Finally, Empirical Finance LLC grew its stake in Edwards Lifesciences by 0.6% in the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock valued at $1,668,000 after purchasing an additional 134 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $83.37 on Wednesday. Edwards Lifesciences has a 1 year low of $64.89 and a 1 year high of $87.09. The business’s fifty day moving average is $77.78 and its two-hundred day moving average is $77.31. The stock has a market capitalization of $48.95 billion, a P/E ratio of 12.00, a P/E/G ratio of 3.97 and a beta of 1.03. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.